Arkolith/Insider Trading/RNA/Form 4

Boyce Sarah

President and CEO, DirectorAvidity Biosciences, Inc. (RNA) · full profile →Form 4 · filed Sep 5, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$2.5M
Net Open-Market Flow
-$2.5M
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Sep 5, 2025Sell(S)50K$49.95$2.5M306K
Sep 5, 2025Option exercise(M)50K$1.24$62K356K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Sep 5, 2025Option exercise(M)50K—$01.0M

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001599901-25-000175) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML

Keep exploring

Connected pages for Avidity Biosciences, Inc.

Build

Ask your agent about RNA insider filings

This filing is the Follow view. The Build view lets your agent pull every Form 4 for the issuer, the net open-market picture over 90 days, and the accession behind each row, through REST or MCP.

Get a key Compare plansForm 4 data
Copy-paste
curl -H "Authorization: Bearer YOUR_API_KEY" \
  "https://arkolith.com/api/v1/filing/0001599901-25-000175"
Ask your agent
Use Arkolith to summarize insider buying and selling at Avidity Biosciences, Inc.
over the last 90 days and cite the filings.